within Pharmacolibrary.Drugs.ATC.C;

model C02DB01
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0004166666666666667,
    adminDuration  = 600,
    adminMass      = 25 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0025,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C02DB01</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Dihydralazine is a direct-acting vasodilator of the hydrazinophthalazine class, related to hydralazine. It was previously used in the management of moderate to severe hypertension, especially in parenteral administration for hypertensive emergencies, but it is not commonly approved or widely used today in many countries.</p><h4>Pharmacokinetics</h4><p>Estimated one-compartment model pharmacokinetic parameters for an adult population based on limited published information; specific studies are lacking.</p><h4>References</h4><ol><li><p>Siegmund, W, et al., &amp; Hüller, H (1987). [Pharmacokinetics of dihydralazine following intravenous administration in laboratory animals]. <i>Die Pharmazie</i> 42(8) 527–530. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3432333/\">https://pubmed.ncbi.nlm.nih.gov/3432333</a></p></li><li><p>Dooley, M, &amp; Goa, KL (1998). Urapidil. A reappraisal of its use in the management of hypertension. <i>Drugs</i> 56(5) 929–955. DOI:<a href=\"https://doi.org/10.2165/00003495-199856050-00016\">10.2165/00003495-199856050-00016</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9829161/\">https://pubmed.ncbi.nlm.nih.gov/9829161</a></p></li><li><p>Reimann, IW, et al., &amp; Frölich, JC (1985). Influence of prostaglandin inhibition on dihydralazine induced acute effects in patients with essential hypertension. <i>Clinical and experimental pharmacology &amp; physiology</i> 12(1) 79–89. DOI:<a href=\"https://doi.org/10.1111/j.1440-1681.1985.tb00306.x\">10.1111/j.1440-1681.1985.tb00306.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3891171/\">https://pubmed.ncbi.nlm.nih.gov/3891171</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C02DB01;
